Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response

NEW BRUNSWICK, N.J., July 1, 2021 – Johnson &Johnson (NYSE: JNJ) (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. The two preprint study summaries have been submitted today to bioRxiv. “Today’s newly announced studies reinforce the ability of the Johnson &Johnson COVID-19 vaccine to help protect the health of people globally,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson &Johnson. “We believe that our vaccine offers durable protection against COVID-19 and elicits neutralizing activity against the Delta variant. This adds to the robust body of clinical data supporting our single-shot vaccine’s ability to protect against multiple variants of concern.” “Current data for the eight months studied so far show that the single-shot Johnson &Johnson COVID-19 vaccine generates a strong neutralizing antibody response that does not wane; rather, we observe an improvement over time. In addition, we observe a persistent and particularly robust, durable cellular immune response,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research &...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news

Related Links:

"I think the biggest challenge for the health care field in the next decade will be determining the next course of action in the face of the gaps exposed throughout the pandemic," Mona Veiseh said.
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news
The $500 million project targets mRNA vaccines for COVID-19 and other viral infections
Source: Chemical and Engineering News - Category: Chemistry Authors: Source Type: research
"I think the biggest challenge for the health care field in the next decade will be determining the next course of action in the face of the gaps exposed throughout the pandemic," Mona Veiseh said.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Ohio ranks among the least safe states during the Covid-19 pandemic, according to a new study. The Buckeye State ranks No. 47 in personal finance website Wallethub’s report “Safest States During Covid-19," which was released Oct. 14. Researchers compared the 50 states and District of Columbia across five key metrics (based on data available as of 12:30 p.m. Oct. 13). Here is how Ohio f ared in each category: Vaccination rate: No. 42 Positive testing rate: No. 43 Hospitalization rate: No. 44 Death…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news
ConclusionThe national birth prevalence for omphalocele in Sweden is 1/10,000 newborn, with high termination rates. Over half of the pregnancies with prenatally diagnosed omphalocele will be terminated. Among those who continue the pregnancy, 1-year survival rates are high.Type of studyNational register studyLevel of evidenceIII.
Source: Pediatric Surgery International - Category: Surgery Source Type: research
ConclusionIn the follow-up of children and adolescents with CCM during the first UK lockdown using telemedicine we found that over half had stable health conditions. Patients needing additional care could not be predicted by the severity of their disease or their bowel function alone.
Source: Pediatric Surgery International - Category: Surgery Source Type: research
Conclusions Higher CRF associated with decreased probability of clinical HBP, lower insulin resistance, and improved liver function in children with EA. Yet blood pressure percentiles and kidney function improved with increasing CRF irrespective of adiposity status.
Source: Medicine and Science in Sports and Exercise - Category: Sports Medicine Tags: CLINICAL SCIENCES Source Type: research
NEW BRUNSWICK, N.J., April 21, 2021 – Johnson &Johnson (the Company) today announced publication in the New England Journal of Medicine of primary data from the Phase 3 ENSEMBLE clinical trial for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson &Johnson (Janssen). The publication of the primary analysis follows the topline efficacy and safety data announced in January, showing the trial met all primary and key secondary endpoints, and found that the Johnson &Johnson single-dose COVID-19 vaccine prevented hospitalization and death across all study participants...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news
NEW BRUNSWICK, N.J., February 28, 2021 – Johnson &Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the first single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson &Johnson, for individuals 18 years of age and older under the Emergency Use Authorization (EUA) issued by the U.S. Food and Drug Administration (FDA). “For more than 130 years, Johnson &Johnson has come to the aid of people during times of crisis, and we believe tod...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
NEW BRUNSWICK, N.J., February 27, 2021 – Johnson &Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson &Johnson, to prevent COVID-19 in individuals 18 years of age and older. This decision was based on the totality of scientific evidence, including data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 85 percent effective in preventing severe disease across all regions studied, and showed protection agains...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news
More News: African Health | Allergy | Allergy & Immunology | Biotechnology | Bleeding | Brain | Brazil Health | Cancer & Oncology | Cardiology | Cardiovascular | Chemistry | Clinical Trials | Contracts | Coronavirus | COVID-19 | Department of Health | Ebola | Ebola Vaccine | Emergency Medicine | Environmental Health | Flu Pandemic | Headache | Health Management | Heart | Hospitals | Hypertension | Infectious Diseases | Influenza | Influenza Vaccine | International Medicine & Public Health | Israel Health | Learning | Legislation | Marketing | Men | Middle East Health | Migraine | National Institutes of Health (NIH) | Neurology | Neuroscience | Pain | Pandemics | Pharmaceuticals | Pregnancy | Profits and Losses | Pulmonary Hypertension | Respiratory Medicine | SARS | Science | Skin | South Africa Health | Study | Universities & Medical Training | USA Health | Vaccines | WHO